Laura Morton Newhouser, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2813 Industrial Park Rd, Mifflintown, PA 17059 Phone: 717-436-8283 Fax: 717-436-8351 |
Dr. Rahul Shenoy, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 27 Cjems Ln, Mifflintown, PA 17059 Phone: 717-436-5578 |
Mandy Louise Maneval, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2813 Industrial Park Rd, Mifflintown, PA 17059 Phone: 717-436-8283 Fax: 717-436-5594 |
Todd Alan Taylor, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2813 Industrial Park Rd, Mifflintown, PA 17059 Phone: 717-436-8283 Fax: 717-436-5594 |
Kenneth Lee Erdman Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2813 Industrial Park Rd, Mifflintown, PA 17059 Phone: 717-436-8283 Fax: 717-436-5594 |
Dr. Kristen Lianne Frank-dixon, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2813 Industrial Park Rd, Mifflintown, PA 17059 Phone: 717-436-8283 Fax: 717-436-8351 |
Dr. Manasi Badve, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 27 Cjems Ln, Mifflintown, PA 17059 Phone: 717-436-0129 Fax: 717-436-0130 |
News Archive
The long-term effects of teasing or harassment by their peers on pre-adolescent children - specifically, depression and anxiety - are related, in part, to the level of victimization at the end of fourth grade, as well as to how much that harassment increased or decreased between fourth and sixth grade, according to a study published in the September/October issue of the journal Child Development.
In 1994, the team of Tchernev and Petrova from Alexandrovska Hospital in Sofia examined a female patient with liver cirrhosis caused by chronic Hepatitis C virus (HCV).
As the agency seeks to increase its ability to provide services, Secretary Eric Shinseki says when patients will get more access to private clinics and hospitals in areas where the department's services are limited.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
› Verified 2 days ago